Family

+

−

Country	kind	publication No.	Filing Date	Type	Sub-Type
US	B2	US9789087	Aug 02, 2016	Patent	Grant
Type : Patent Sub-Type : Grant
GRANTED PATENT AS SECOND PUBLICATION		PAR4 inhibitor therapy for patients with PAR4 polymorphism		Oct 17, 2017

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
THOMAS JEFFERSON UNIVERSITY	PHILADELPHIA PA

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
• C12Q:MEASURING OR TESTING PROCESSES INVOLVING ENZYMES O....

• 2017 Application Filing Year
• A61K Class
• 21227 Applications Filed
• 12841 Patents Issued To-Date
• 60.50 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Bray, Paul	Philadelphia, US	3	4
# of filed Patents : 3 Total Citations : 4
Edelstein, Leonard	Philadelphia, US	2	3
# of filed Patents : 2 Total Citations : 3
Holinstat, Michael	Ann Arbor, US	14	13
# of filed Patents : 14 Total Citations : 13

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 7 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Jul 4, 2025
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Jul 4, 2029

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2018/0000,784

PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM

---

Abstract

---

Disclosed herein are methods for determining whether a PAR4 inhibitor should be administered to a human subject, the methods comprising administering a PAR4 inhibitor to a subject determined to have a 'G' allele for a single-nucleotide polymorphism (SNP) at rs773902, and not administering a PAR4 inhibitor to a subject determined to have an 'A' allele for the SNP at rs773902. A genotyping assay can be used to determine the SNP.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.